Frontlight ResearchEarly access
CompletedNo phase
Evaluation of the Bifurcated Multilayer Flow Modulator for the Treatment of Abdominal Aortic Aneurysm
Key facts
- Who runs it
- Cardiatis
- Where
- Belgium, Bulgaria, Morocco, Romania, and Slovenia7 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 42 people enrolled
- Started
- 11 Apr 2014
- Ended
- 7 Dec 2023
- Type of study
- Interventional
- Treatments tested
- Implantation of the Bifurcated Multilayer Flow Modulator
- Record updated
- 3 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Patients must meet ALL of the following criteria:
- Age over 18
- Life expectancy > 12 months
- Aortic aneurysms involving iliac arteries
- Healthy proximal and distal landing zone
- Adequate arterial access
- Healthy branches and collaterals (no stenosis or previously treated by angioplasty)
- Informed consent understood, signed and patient agrees to all follow-up visits
Who cannot take part
- Prior all surgical procedure within 30 days unless procedure is in preparation for device implantation or planned within 30 days post stent deployment
- Contraindications to the anticoagulant or/ and antiplatelet medications
- Patient with undergoing or planned chemotherapy
- The use of the MFM® with stent-grafts or previously implanted stent-grafts
- Patients will be excluded if ANY of the following conditions apply:
- Myocardial infarction or cerebral vascular accident within 6 weeks of treatment
- Presence/suspicion of connective tissue disorders, for example, Marfan or Ehlers-Danlos etc
- Allergic reaction to a contrast agent
- History of bleeding disorder (coagulopathy) or thrombophilia
- Presence/suspicion of infection (for example: mycotic aorta)
- Aneurysm rupture, impending or contained rupture
- Aortic dissection
- Aortic root aneurysm
- Pleural effusion
- Shaggy aorta
- Takayasu's arteritis
- Pregnant or breastfeeding woman
- Patients included in another clinical study
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study purpose is to determine the safety and efficacy of the BMFM used for the endovascular treatment of aortic aneurysm involving iliac arteries. The BMFM is an adaptation of the aortic MFM® to the aorto-iliac bifurcation anatomy. It should be noted that the aortic MFM® has CE mark approval for the aortic aneurysm treatment.
The group in the trial
- treatmentTreatment being tested
aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
Treatment: Implantation of the Bifurcated Multilayer Flow Modulator
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Safety and Performance of the BMFM® Kit (Bifurcated Multilayer Flow Modulator) for the Treatment of Abdominal Aortic Aneurysm
- Record updated
- 3 September 2026